First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting ...

Charles Kim Haskell told Newsweek he once thought he wouldn't live beyond his teenage years, but, at 31, he is enjoying his life.

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Dominion Energy is the kind of stable utility stock that's great to own during turbulent markets. Enbridge has a lower risk ...

BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical ...

Autonomy, confidence and competence were stronger predictors of wellbeing than more traditional measures like deprivation or ...

Investing.com -- BiomX (NYSE: PHGE) Inc. (NYSE American:PHGE) stock surged 60% after the clinical-stage company announced it has successfully initiated patient dosing in its Phase 2b trial evaluating ...

A Ph.D. graduate student in biomolecular engineering at UC Santa Cruz, with a background in computer science and mathematics, ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Supporters are gearing up for two charity football games across Bristol in aid of the Cystic Fibrosis Comfort Fund. The first ...

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...